The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

被引：202

作者：

Straver, Marieke E. ^{[2
]}

Glas, Annuska M. ^{[3
]}

Hannemann, Juliane ^{[4
]}

Wesseling, Jelle ^{[4
]}

van de Vijver, Marc J. ^{[4
]}

Rutgers, Emiel J. Th. ^{[2
]}

Peeters, Marie-Jeanne T. F. D. Vrancken ^{[2
]}

van Tinteren, Harm ^{[5
]}

van't Veer, Laura J. ^{[3
,4
]}

Rodenhuis, Sjoerd ^{[1
]}

机构：

[1] Antoni van Leeuwenhoek Hosp, Dept Med Oncol, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands

[2] Antoni van Leeuwenhoek Hosp, Dept Surg Oncol, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands

[3] Agendia BV, NL-1098 XH Amsterdam, Netherlands

[4] Antoni van Leeuwenhoek Hosp, Dept Pathol, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands

[5] Antoni van Leeuwenhoek Hosp, Dept Biometr, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2010年 / 119卷 / 03期

关键词：

Breast cancer; Neoadjuvant; Chemosensitivity; Predictive; Gene expression signature; GENE-EXPRESSION PROFILES; PHASE-II TRIAL; PREOPERATIVE CHEMOTHERAPY; CLINICAL UTILITY; IN-SITU; WOMEN; THERAPY;

D O I：

10.1007/s10549-009-0333-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The 70-gene signature (MammaPrint (TM)) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II-III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.

引用

页码：551 / 558

页数：8

共 28 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) [J].

不详 .

LANCET ONCOLOGY, 2007, 8 (12) :1079-1087

[3] Validation of 70-gene prognosis signature in node-negative breast cancer [J].

Bueno-de-Mesquita, J. M. ;

Linn, S. C. ;

Keijzer, R. ;

Wesseling, J. ;

Nuyten, D. S. A. ;

van Krimpen, C. ;

Meijers, C. ;

de Graaf, P. W. ;

Bos, M. M. E. M. ;

Hart, A. A. M. ;

Rutgers, E. J. T. ;

Peterse, J. L. ;

Halfwerk, H. ;

de Groot, R. ;

Pronk, A. ;

Floore, A. N. ;

Glas, A. M. ;

van't Veer, L. J. ;

van de Vijver, M. J. .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (03) :483-495

[4] Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer [J].

Burris, H ;

Yardley, D ;

Jones, S ;

Houston, G ;

Broome, C ;

Thompson, D ;

Greco, FA ;

White, M ;

Hainsworth, J .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1621-1629

[5] Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer [J].

Buyse, Marc ;

Loi, Sherene ;

van't Veer, Laura ;

Viale, Giuseppe ;

Delorenzi, Mauro ;

Glas, Annuska M. ;

d'Assignies, Mahasti Saghatchian ;

Bergh, Jonas ;

Lidereau, Rosette ;

Ellis, Paul ;

Harris, Adrian ;

Bogaerts, Jan ;

Therasse, Patrick ;

Floore, Arno ;

Amakrane, Mohamed ;

Piette, Fanny ;

Rutgers, Emiel ;

Sotiriou, Christos ;

Cardoso, Fatima ;

Piccart, Martine J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17) :1183-1192

[6] Clinical application of the 70-gene profile: The MINDACT trial [J].

Cardoso, Fatima ;

Van't Veer, Laura ;

Rutgers, Emiel ;

Loi, Sherene ;

Mook, Stella ;

Piccart-Gebhart, Martine J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) :729-735

[7] The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].

Carey, Lisa A. ;

Dees, E. Claire ;

Sawyer, Lynda ;

Gatti, Lisa ;

Moore, Dominic T. ;

Collichio, Frances ;

Ollila, David W. ;

Sartor, Carolyn I. ;

Graham, Mark L. ;

Perou, Charles M. .

CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334

[8] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].

Citron, ML ;

Berry, DA ;

Cirrincione, C ;

Hudis, C ;

Winer, EP ;

Gradishar, WJ ;

Davidson, NE ;

Martino, S ;

Livingston, R ;

Ingle, JN ;

Perez, EA ;

Carpenter, J ;

Hurd, D ;

Holland, JF ;

Smith, BL ;

Sartor, CI ;

Leung, EH ;

Abrams, J ;

Schilsky, RL ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439

[9]

Elston C W, 2002, Histopathology, V41, P154

[10] Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer [J].

Gianni, L ;

Zambetti, M ;

Clark, K ;

Baker, J ;

Cronin, M ;

Wu, J ;

Mariani, G ;

Rodriguez, J ;

Carcangiu, M ;

Watson, D ;

Valagussa, P ;

Rouzier, R ;

Symmans, WF ;

Ross, JS ;

Hortobagyi, GN ;

Pusztai, L ;

Shak, S .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (29) :7265-7277

← 1 2 3 →